1 / 43

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome. Obstetrics & Gynecology Vol 103, No 1, Jau 2004 부산백병원 산부인과 R4 강영미. Introduction. Chronic anovulation and androgen excess not attributable to another cause Occurs in approximately 4% of women Fundamental pathophysiologic defect Unknown

alder
Download Presentation

Polycystic Ovary Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Polycystic Ovary Syndrome Obstetrics & Gynecology Vol 103, No 1, Jau 2004 부산백병원 산부인과 R4 강영미

  2. Introduction • Chronic anovulation and androgen excess not attributable to another cause • Occurs in approximately 4% of women • Fundamental pathophysiologic defect • Unknown • Important characteristics ; insulin resistance, hyperandrogenism, and altered gonadotropin dynamics • Inadequate FSH ; hypothesized to be a proximate cause of anovulation • Obesity complicates PCOS but is not a defining characteristic

  3. Introduction • Diagnostic approach ; should based on history and physical exam • Irregular bleeding, hirsutism and/or infertility • Treated with OCs, OCs with spironolactone and ovulation induction • Higher prevalence of diabetes and increased risk factors for cardiovascular ds. • should also be screened • for obese women with PCOS, behavioral weight management ; central component of the overall treatmentstrategy

  4. Definition • Since its first description in 1935, a variety of histologic, biochemical, sonographic and clinical characteristics ; associated with PCOS • Practical and useful clinical definition of PCOS in the United States • If have chronic anovulation and evidence of androgen excess for which there is no other cause • Referred to as the "NIH Conference" definition, despite wide variety of views regarding the clinical, endocrinologic features (Table 1)

  5. Prevalence • Best prevalence study, reported in 1998, with unselected sample of white and African-American women between the ages of 18 and 45 years • 277 women who consented to a history, physical exam, and hormonal evaluation, overall prevalence of PCOS • 4-4.7% for white women • 3.4% for African American women

  6. Clinical Importance • In clinical gynecologic practice, • Primarily for menstrual irregularity, hirsutism, and infertility • Treatment is directed at the immediate presenting complaint • Long-term goals • Prevent diabetes, coronary heart ds. • Screen cancer • Unopposed estrogen exposure -> increased risk of endometrial ca.

  7. Pathophysiology • Fundamental pathophysiologic defect in PCOS • Unknown • Several interrelated characteristics ; insulin resistance, hyperandrogenism,and altered gonadotropin dynamics • Hypothesis that inadequate FSH stimulation ; proximate cause of anovulation in PCOS

  8. Pathophysiology • Insulin resistance • Defined as a subnormal biological response to insulin • Associated with obesity • Extent of insulin resistance - cannot be explained entirely by obesity

  9. Pathophysiology • Hyperandrogenism • strong correlation between insulin resistance and hyperandrogenism • HAIR-AN syndrome • Acanthosis nigricans • Strongly suggests insulin resistance • Dermatologic disorder characterized by velvety hyperpigmented skin, usually over the nape of the neck, in the axillae, or beneath the breasts)

  10. Pathophysiology • what is the directionality of the relationship between insulin resistance andhyperandrogenism? • Direction of causation is from insulin to androgen and not reverse • Administration of diazoxide -> results in reduction in circulating androgenconcentrations • Weight loss and insulin sensitizers -> reduction in androgen • in vivo effect on ovarian androgens by insulin • insulin synergizes with LH to promote androgen production by the thecalcells

  11. Pathophysiology • Altered gonadotropin-releasing hormone dynamics • Another key pathophysiologic feature of PCOS • Increased LH pulse frequency and amplitude, leading to increased 24-hour mean concentrations in both lean and obese women with PCOS • Elevated LH levels • Responsible for the excess androgen production • Androgen production by theca cell is LH dependent • Suppression of LH by GnRH agonists or by OCs reduces circulatingtestosterone and androstenedione

  12. Pathophysiology • Inadequate concentrations of endogenous FSH • Absolute concentrations of FSH above a specified threshold • Essential for both the initiation of preovulatory follicle development as well as the selection of a single preovulatory follicle

  13. Pathophysiology • In PCOS, • E2 production ; limited • Follicles not mature fully • Granulosa cells number and in aromataseactivity decreased • Therefore, E2 production is limited, in the range of 70-80 pg/mL higher thanearly follicular E2 • Suppressing FSH, but never reaching the levels needed toinitiate an LH surge • Concentration of FSH • Not rise above levels seen in the mid-follicular range • Insufficient to stimulate preovulatroy follicle development • Constrained by negative feedbackinhibition of E2 which never exceeds mid-follicular levels

  14. Pathophysiology • Currently lack a satisfactory integrative model of PCOS pathophysiology • Genetic factors are at the root of the condition • In view of characteristics such as insulin resistance and gonadotropin changes • Likely that more than one genetic "hit" • Influenced by environmental factors

  15. Diagnostic Approach • Relatively safe ground on combination of chronic anovulation and androgen excess • With respect to ovulatory history • History of irregular menstrual cycles dating to menarche • Report 6 or fewer episodes of spontaneous vaginal bleeding per year

  16. Diagnostic Approach • oily skin and acne • subtle signs of androgen excess • Hirsutism • Mostcommon manifestation of the androgen component of PCOS • should inquire about and examine for • "male-pattern" hair(hair locatedon the upper lip, chin, chest, lower abdomen, and inner aspects of the thighs)

  17. Diagnostic Approach • Differing opinions on what laboratory studies should be ordered in evaluating a woman with PCOS • Primarily a clinical diagnosis - few laboratory studies are needed • Only condition that needs to be excluded to secure the diagnosis of PCOS - nonclassical CAH • Diagnostic pathway in Figure 3

  18. Diagnostic Approach • Figure 3

  19. Diagnostic Approach • Ratio of LH to FSH greater than 2;1 - consistent with PCOS • LH ; FSH ratio often in the "normal range" ∵ pulsatile nature of gonadotropins, resulting in broad range of LH ; FSH ratiosin PCOS when a single blood sample is drawn • In author's practice, evaluating a women with chronic anovulation since menarche and hirsutism • Only blood sample - 17-hydroxyprogesterone concentration to rule out21-hydroxylase-deficient nonclassical adrenal hyperplasia

  20. Diagnostic Approach • Testosterone • Not necessary for diagnosis when clear hirsutism is present • Sometimes helpful in evaluating a women with chronic anovulation but who doesnot have clinical evidence of hirsutism or other signs of androgen excess • Total testosteroneconcentration greater than 60 ng/dL ; consistent with PCOS

  21. Diagnostic Approach • Ovarian anatomy • Show multiple, small, subcapsular cysts, reflecting repeated episodes of incomplete follicular growth • Dense, hyperplastic stroma, reflecting an active thecal component that is over-secreting androgens • Ultrasound picture • Numerous, small subcapsular cysts that produces a "string of pearls" sign(Figure4) • Small subcapsular cysts and hyperechogenic stroma

  22. Diagnostic Approach • Figure 4

  23. Diagnostic Approach • In summary, • Best diagnosed clinically with a minimum of laboratory tests • History of chronic anovulation dating since menarche • Evidence of androgenexcess, principally hirsutism • Blood sample for serum 17-hydroxyprogesteroneconcentration to rule-out 21-hydroxylase-deficient nonclassical adrenal hyperplasia • Obesity in conjunction with anovulation and androgen excess • Increase furtherone's suspicion of PCOS

  24. Diagnostic Approach • In cases in which the clinical diagnosis is not clear • Chronic anovulation withouthirsutism • Hirsutism with a history of cyclic menses • Obesity ; increases the clinical suspicion of PCOS • Serum testosterone greater than 60 ng/dL ; suggests diagnosis of PCOS

  25. Long-term risk of PCOS • Increased risk of endometrial cancer ∵ Unopposed estrogen that results from chronic anovulation • In recent years, diabetes and cardiovascular ds.

  26. Long-term risk of PCOS • Dramatically increased risk of impaired glucose tolerance and non-insulin-dependent diabetes mellitus • Fasting glucose concentrations - poor predictors of non-insulin-dependentdiabetes mellitus ∵ As shown in Figure 5, women with PCOS - Normal fasting glucose concentration - IGT and DM based on 2-hour oral glucose tolerance test value • 30% for IGT, 8-10% DM(Figure 6)

  27. Long-term risk of PCOS

  28. Long-term risk of PCOS • Do the diabetes, adverse lipid profile and preclinical atherosclerotic changes seen in women with PCOS translate into an increase in actual cardiovascular events? • Limited and inconsistent • Clear need for a prospective study

  29. Treatment • Figure 8

  30. Treatment • Patient's height and weight to calculate her body mass index • BP at the first visit • Fasting lipid panel to evaluate cardiovascular risk • Fasting glucose concentration to evlauate the possibility of IGT or non-insulin-dependent diabetes mellitus • 2-hour oral glucose tolerance test is preferable

  31. Treatment • In overweight patient(body mass index 26 or higher), major component of any treatment should be directed at weight reduction • Best weight loss strategy - integrated behavioral program • Include exercise, moderate calorie restriction • Result in significant favorable impact on insulin, androgens, and ovulation • No data on long-term outcomes of such lifestyle modification programs

  32. Treatment • Initial therapeutic strategy in the management of PCOS • Behavioral weight management in obese patients follows directly from the patient's chief complaint • Metformin - not sliver bullet for all aspects of PCOS treatment

  33. Treatment • Irregular menstruation • Without the additional concerns of hirsutism or infertility • OCs remain an excellent choice • Present hirsutism • OCs plus spironolactone, at a dose of 200 mg/d is standard choice

  34. Treatment • Several clear benefits in the treatment of irregular menstrual cycles in womenwith PCOS • 1.Regular withdrawal bleeding • 2. Reduction in the risk of endometrial hyperplasia or cancer because ofprogestin opposition of estrogen • 3. Reduction in LH secretion and consequent reduction of ovarian androgens • 4. Increased sex hormone binding globulin production and consequent reduction in free testosterone • 5. Improvement in hirsutism and acne • Measruable decline in hirsutism after 6 months of treatment, while noeffect on hirsutism was seen with metformin

  35. Treatment • Common reason for a physician consultation ; infertility • Assuming a normal semen analysis, ovulation induction • Recommended approach in Figure 9 • Hysterosalpingography to confirm a normal genital tract if history of PID, endometriosis, or previous abdominal surgery

  36. Treatment • Figure 9

  37. Treatment • Most physiologic approach to ovulation induction ; weight loss • Failing that -> clomiphene citrate • Excellent initial pharmacologic strategy • Use the lowest clomiphene citrate dose that will initiate the smallest numberof ovulatory follicles(hopefully, only one!) • Starting dose ; 50 mg/d for 5 days(usually days 5-9) • approximately 50% ovulation on 50 mg

  38. Treatment • Ultrasound on day 13 to assess follicle development • More than 2 preovulatory follicles on day 13 ; reduced to 25 mg/d insubsequent cycles • No follicle development ; dose and duration of treatment increased • Never exceed 150 mg/d for 5 days • Once regimen that induces ovulation if there is no pregnancy • Should repeat that regimen and not increase the dose in subsequent cycles -> Goal is ovulation, not superovulation • Overall, approximately 80% of women with PCOS - ovulate on clomiphenecitrate

  39. Treatment • How should ovulation be induced in the 20% of women who are refractory to clomiphene citrate? • Use of metformin hydrochloride • Common and effective strategy • Used extensively in the treatment of non-insulin-dependent diabetes mellitus • Helps with glycemic control by reducing hepatic glucose output and by increasing peripheral uptake of glucose • Kidney or liver ds., alcoholism, heart failure treated with furosemide should not take metformin ∵ lactic acidosis risk ↑ • Begun at a dose of 500 mg/d to minimize gastrointestinal side effects and increased gradually as tolerated

  40. Treatment • Small percentage of women with PCOS (about 5-10%) who are refractory to clomiphene citrate alone and to metformin plus clomiphene citrate or who cannot tolerate these medications • Laparoscopic ovarian drilling or injectable gonadotropin • Gonadotropins • Hypersensitive to exogenous FSH • Risk of multiple pregnancy and hyperstimulation • Should be used in conjunction with in vitro fertilization ; Number of embryos that are transferred to the uterine cavity controlled

  41. Follow-Up • Women with PCOS who are being seen for infertility • Followed closely with regards to ovulation induction • If no pregnancy after 6 months of documented ovulation • Additional infertility evaluation • If no pregnancy after 9-12 months of documented ovulation, and if no otherinfertility factors • Blend with unexplained infertility • Intrauterine insemination is added • If lack of pregnancy despite multiple cycles of ovulation induction andintrauterine insemination • Lead to consideration of the use of gonadotropins

  42. Follow-Up • For women with PCOS who are not interested in pregnancy • Follow-up at 6 month intervals

More Related